Topamax (topiramate) Tablets/Sprinkle Capsules - Jul 10, 2003
July 10, 2003
Audience: Neurologists, Pediatricians, and other Healthcare professionals
Ortho-McNeil and FDA revised the WARNINGS and PRECAUTIONS sections of the prescribing information to provide updated information about oligohidrosis (decreased sweating) and hyperthermia, which have been reported in topiramate-treated patients. Oligohidrosis and hyperthermia may have potentially serious sequelae, which may be preventable by prompt recognition of symptoms and appropriate treatment.[July 9, 2003 Letter - Ortho-McNeil] PDF Format
[June, 2003 Revised label - Ortho-McNeil] PDF Format
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.